Evidence is accumulating that chronic inflammation may have an important role in prostate cancer (PCa). Three common polymorphisms in the promoter of interleukin-10 (IL-10) gene, À1082 A4G, À819 C4T and À592 C4A, have been implicated to alter the risk of PCa, but the results of relative studies are inconclusive or controversial. To derive a more precise estimation of the relationship, we performed an updated meta-analysis on the basis of 10 studies. A comprehensive search was conducted to examine all the eligible studies of IL-10 polymorphism and PCa risk. We used odds ratios (ORs) to assess the strength of the association, and 95% confidence intervals (CIs) give a sense of the precision of the estimate. Overall, there were no significant associations between increased risk of PCa and IL-10 À1082 A4G, À819 C4T and À592 C4A polymorphisms. However, meta-analysis suggested that IL-10 À819 C4T and À592 C4A polymorphisms might be modestly associated with PCa aggressiveness (T versus C, OR ¼ 1.162, 95% CI: 1.035-1.305, P ¼ 0.011; A versus C, OR ¼ 1.131, 95% CI: 1.012-1.264, P ¼ 0.030; respectively). IL-10 À819 C4T and À592 C4A polymorphisms might impact PCa progression. Variant alleles at both À819 and À592 were modestly associated with advanced stages of PCa. Additional well-designed studies are warranted to validate these findings.
Introduction
Prostate cancer (PCa) is one of the most common malignancies of males in western countries. 1 The underlying etiology of PCa is poorly understood, with genetic predisposition and environmental factors likely contributing to risk. 2 It can be difficult to separate the effects of both types of factors. The most recognized factors associated with PCa risk are ethnicity, age and family history of the disease. Besides, studies have reported that both endogenous\exogenous hormonal substances and some gene polymorphisms could be potential risk factors of PCa. 3, 4, 5 Recent studies suggest that genetic polymorphisms of genes involved in innate immunity and chronic inflammation, including the anti-inflammatory cytokine interleukin-10 (IL-10), might impact susceptibility to PCa. 6, 7 The IL-10 gene is comprised of five exons, spans B5.2 kb and is located at 1q31-1q32. 8 IL-10 is a pleiotropic cytokine with both anti-inflammatory and antiangiogenic properties. The anti-inflammatory properties of IL-10 are hypothesized to have protumorigenic potential by enabling tumor cells to escape immune surveillance. The antiangiogenic properties of IL-10 are hypothesized to have antitumorigenic potential, as in both animal and in vitro models, by reducing both tumor growth and angiogenesis. 9 Previous reports showed that reduced levels of IL10 have been associated with the presence of the IL10 À1082G/À819T/À592A haplotype on the IL-10 gene promoter 10, 11 as well as with increased risk of cancer in several populations. 12, 13, 14 Hence, in recent studies, three common polymorphisms in the promoter of the IL-10 gene, À1082 (rs1800896) A4G, À819 (rs1800871) C4T and À592(rs1800872) C4A, have been extensively studied in PCa. 15 However, results of studies that examined the association of the three singlenucleotide polymorphisms (SNPs) to the incidence of PCa have been contradictory. Some studies have found that IL-10 À1082 A4G polymorphism increases the risk of PCa, whereas others failed to confirm this observation. The remaining two SNPs À819 C4T and À592 C4A encountered the same situations.
To overcome limitations of individual genetic association studies and derive a more precise estimation of the association between IL-10 À1082 A4G, À819 C4T and À592 C4A polymorphisms and PCa risk, we performed a meta-analysis of all eligible case-control studies and to explore the between-study heterogeneity and potential bias.
Materials and methods

Publication search
PubMed and EMBASE were searched using the search terms: 'IL-10' and 'PCa' (last search was updated on 8 October 2010). All published English language papers with available full text matching the eligible criteria were retrieved. Additional studies were identified by a hand search of the references of original studies. Of the studies with overlapping data published by the same investigators, only the most recent or complete study was included in this meta-analysis.
Inclusion and exclusion criteria
For inclusion in the meta-analysis, the identified articles had to provide: (1) information on the evaluation of IL-10 (À1082 A4G, À819 C4T and À592 C4A) polymorphisms and PCa risk, (2) sufficient published data for evaluating the odds ratio (OR) with 95% confidence interval (CI), (3) using a case-control design and (4) containing available genotype frequency data on cases and controls in the study. The major reasons for exclusion of studies were: (1) no control population, (2) no usable data reported and (3) duplicates.
Data extraction
All of the data were extracted independently by two reviewers according to the prespecified inclusion criteria, and reached a consensus on all the items. For each study, the following characteristics were collected: the first author's last name, year of publication, country of origin, ethnicity, numbers of genotyped cases and controls, and stage of case group (early stage or advanced stage of PCa cases; we defined early stage or advanced stage of PCa cases on the basis of tumor stage and Gleason score). A case was considered 'advanced' if it was diagnosed with extraprostatic extension or metastasis (stages III or IV) or with Gleason score X7 16 ), genotyping methods and quality control. Different ethnic descents were categorized as Caucasian, Asian, African and Mixed, which included more than one ethnic descent. For studies including subjects of familial or sporadic PCa cases, data were extracted separately for each group whenever possible.
Statistical analysis
The strength of the association between IL-10 À1082 A4G, À819 C4T and À592 C4A polymorphisms, and PCa risk was measured by ORs, whereas a sense of the precision of the estimate was given by 95% CIs. The significance of the summary OR was determined with a Z-test. For IL-10 À1082 A4G polymorphism, we first explored the association between allele G and PCa risk, as well as heterozygote comparison GA versus AA, homozygote comparison GG versus AA, dominant genetic model GG/GA versus AA and recessive genetic model GG versus GA/AA. For IL-10 À819 C4T and À592 C4A polymorphisms, we evaluated the same effects. Stratified analyses were also performed by ethnicities and stages of cases.
Heterogeneity assumption was checked by w 2 -based Q-test. A P-value 40.05 for the Q-test indicated lack of heterogeneity among the studies, and so the summary OR estimate of each study was calculated by the fixedeffects model (the Mantel-Haenszel method). Otherwise, the random-effects model (DerSimonian and Laird method) was used. 25, 26 The significance of the pooled OR was determined by the Z-test and Po0.05 was considered as statistically significant. To explore the reasons of heterogeneity, subgroup analyses were performed by grouping studies, such as ethnicity and stages of cases. To investigate whether publication bias might affect the validity of the estimates, funnel plot were constructed. An asymmetric plot suggests a possible publication bias. Funnel plot asymmetry was assessed by the method of Egger's linear regression test, a linear regression approach to measure funnel plot asymmetry on the natural logarithm scale of OR. The significance of the intercept was determined by the t-test suggested by Egger (Po0.05 was considered representative of statistically significant publication bias).
All statistical analyses were performed with the Stata software (version 10; StataCorp LP, College Station, TX, USA) using two-sided P-values.
Results
Eligible studies
Total searches yielded 256 entries. However, 55 articles were in both PubMed and EMBASE. Following removal of 55 duplicates, 201 titles and abstracts were assessed. Through the step of screening the title and abstracts, 182 of these papers were excluded because they were not about polymorphisms and PCa risk. A total of 19 articles appeared to be potentially relevant for inclusion into the review. In all, 9 articles were excluded for the following Figure 1 . As a result, there were 10 studies retrieved on the basis of the above search criteria for PCa susceptibility related to IL-10 À1082 A4G, À819 C4T and À592 C4A polymorphisms. 9, [16] [17] [18] [19] [20] [21] [22] [23] [24] The main study characteristics are summarized in Table 1 . There were three studies of subjects of Asian descent 20, 22, 24 and seven studies of subjects of Caucasian descent. and À819 C4T). The remaining four studies included three SNPs. Therefore, there were 9 studies with 3385 cases and 4311 controls concerning the À1082 A4G polymorphism, 6 studies with 2827 cases and 3685 controls concerning the À819 C4T polymorphism and 6 studies with 2243 cases and 2508 controls concerning the À592 C4A polymorphism.
All the studies used frequency-matched controls to the cases by age, sex or ethnicity. A classical PCRrestriction fragment length polymorphism assay was conducted in two studies, 16, 24 a TaqMan assay was used in five studies, 9, 18, 19, 21, 23 and an amplification refractory IL-10 polymorphisms and prostate cancer risk N Shao et al mutation system-PCR technique assay was used in two studies. 17, 22 The last study adopted allele-specific oligonucleotide-PCR method. 20 In addition, there were four studies that investigated the association of IL-10 polymorphisms with PCa aggressiveness. 
Meta-analyses
In the overall À1082 A4G analysis, the GG and AG genotypes were not significantly associated with increased risk of PCa (GG versus AA: OR ¼ 0.851, 95% CI: 0.650-1.115, P ¼ 0.243; GA versus AA: OR ¼ 0.980, 95% CI: 0.808-1.187; and G versus A: OR ¼ 0.941, 95% CI: 0.833-1.062, P ¼ 0.324 Table 2 ). A similar negative association was maintained in dominant and recessive models (GG þ GA versus AA: OR ¼ 1.123, 95% CI: 0.877-1.438, P ¼ 0. 357 and GG versus GA þ AA: OR ¼ 1.062, 95% CI: 0.880-1.281, P ¼ 0.529 Table 2 ). Similarly, the IL-10 À819C4T and À592 C4A polymorphisms were not found significantly associated with increased risk of PCa (date are shown in Tables 3, 4 ). In the stratified analysis by ethnicity, our results do not show any risk of PCa associated with IL-10 À1082 A4G, À819 C4T and À592 C4A polymorphisms among subjects of Asian descent or Caucasian descent.
Additionally, the frequency of the T allele of À819 was modestly higher in advanced-stage PCa patients than in early-PCa patients (OR ¼ 1.162, 95% CI: 1.035-1.305, IL-10 polymorphisms and prostate cancer risk N Shao et al P ¼ 0.011; Table 5 ). At À592, the A allele was also found more frequently in advanced-stage PCa patients than in early-PCa patients (OR ¼ 1.131, 95% CI: 1.012-1.264, P ¼ 0.030; Table 5 ). Taken together, these data identify no significant association between frequency of IL-10 À819 C4T, À592 C4A polymorphisms and incidence of PCa; however, they did reveal an association between frequency of IL-10 À819 C4T, À592 C4A polymorphisms and PCa stage.
Test of heterogeneity
In À1082 A4G polymorphism, the heterogeneity was reckoned between each of the studies using the Qstatistic (G versus A: P heterogeneity ¼ 0.012); homozygote comparison (GG versus AA: P heterogeneity ¼ 0.009); heterozygote comparison (GA versus AA: P heterogeneity ¼ 0.027); dominant model comparison (GG þ GA versus AA: P heterogeneity ¼ 0.019); and recessive model comparison (GG versus GA þ AA: P heterogeneity ¼ 0.001). Although we assessed the source of heterogeneity by ethnicity, genotyping method for homozygote comparison, heterozygote comparison, dominant model comparison and recessive model comparison, we did not find the source of heterogeneity by metaregression. But there was no significant heterogeneity in À819 C4T polymorphisms for the homozygote comparison (TT versus CC: P heterogeneity ¼ 0.177), heterozygote comparison (TC versus CC: P heterogeneity ¼ 0.149) and recessive model comparison (TT versus TC þ CC: P heterogeneity ¼ 0.335), except for dominant model comparison (TT þ TC versus CC: P heterogeneity ¼ 0.041, and T versus C: P heterogeneity ¼ 0.032). There was also no significant heterogeneity in À592 C4A polymorphisms (Table 4) . When it comes to À819 C4T and À592 C4A with PCa stage, the 'negative' results were also observed.
(T versus C: P heterogeneity ¼ 0.400 and A versus C: P heterogeneity ¼ 0.239)
Sensitivity analysis
Although three studies 20, 22, 24 did not follow the HardyWeinberg equilibrium, the summary ORs were not effectively altered with or without including these three studies. Moreover, no other single study influenced the overall results qualitatively as indicated by sensitivity analyses.
Publication bias
Begg's funnel plot and Egger's test were performed to assess the publication bias. The shape of funnel plots did not reveal any evidence of obvious asymmetry in all comparison models, and the Egger's test was used to provide statistical evidence of funnel plot symmetry. The results did not show any evidence of publication bias (dates are shown in Tables 2-4). As for À819 C4T and À592 C4A with PCa stage, the results, likewise, did not show any evidence of publication bias (T versus C: P ¼ 0.870, t ¼ À0.210 and A versus C:
Discussion
We conducted a systematic search of the literature and combined the available results in this meta-analysis, which is a useful strategy for elucidating genetic factors in cancer. 27 IL-10, a pleiotropic cytokine with both antiinflammatory and antiangiogenic properties, has been studied extensively about relationship with different cancers, such as urothelial bladder cancer, cutaneous malignant melanoma, PCa and so on. 28, 29, 37 Previous results of the studies on the relationship between IL-10 polymorphisms and PCa risk were contradictory. These inconsistent results are possibly because of a small effect of the polymorphism on PCa risk or the relatively low statistical power of the published studies; consequently, the meta-analysis was needed to provide a quantitative approach for combining the results of various studies with the same topic, and for estimating and explaining their diversity. 30 The present meta-analysis investigated the association between three polymorphisms in the IL-10 À1082 A4G, À819 C4T and À592 C4A gene region, and PCa risk, based on 10 published case-control studies. We found no significant evidence indicating that differences in allele frequency or genotype distribution for any of the three IL-10 À1082 A4G, À819 C4T and À592 C4A SNPs between patients with PCa and control subjects.
However, modestly higher frequencies of the À819T and À592A allele were observed in advanced-stage patients in comparison with early-stage PCa patients. It may be a possible reflection of the IL-10 polymorphisms' role in the PCa aggressiveness. PCa is an actively progressive disease. Therefore, we believe that it is imperative to establish mechanisms to identify people at risk of developing more aggressive diseases and those who would get more benefit of the current therapies. The importance of inflammation in PCa development is highlighted by the finding that 20% of patients presenting with chronic inflammation in the prostate developed PCa after a 5-year follow-up, when compared with IL-10 polymorphisms and prostate cancer risk N Shao et al patients with no chronic inflammatory changes. 31 For example, a previous report found that the association of IL-10 SNPs with PCa aggressiveness in CaucasianAmerican individuals and cytokine gene-SNP interactions might have a role in this process. 32 Many tumors induce various productions of cytokines, including IL-6, IL-8, IL-10 and tumor necrosis factor, to promote their own growth and limit immune responses. 33, 34 Modulation and interactions of these cytokine productions may be pivotal for the control of inflammation and tumor progression. Besides, recent studies using gene expression assays have been used to predict the survival of patients with lung and colorectal carcinoma 35, 36 and have proven to be more precise in the classification of the disease stage than the current systems. Richardsen 38 also found high expression of COX-2, tumor growth factor-b and Ki67 in metastatic primary prostate carcinoma compared with non-metastatic cancers. Polymorphisms at positions À1082, À819 and À592 in the promoter of the IL-10 gene is a strong determinant for IL-10 expression. 18 So, the association of IL-10 SNPs with PCa aggressiveness may be linked to a gene expression dependent on these promoters, but this is still to be proven. Therefore, future studies were necessary to complement this investigation aiming to set a complete molecular signature of individuals, including gene expression profiles and microRNA expression.
Our analysis has also some strengths and limitations. This article is potentially limited in several ways. First, our search was largely restricted to studies published in indexed journals. This could bias the results of this review such as time-lag bias and publication bias. In time-lag bias, 39 studies with 'negative' results take longer time to be published, whereas enthusiastic results are published much more quickly. In publication bias, 40, 41 small studies with 'negative' results are never published, whereas equally small studies with similar quality but 'positive' results would appear in the literature. We saw no evidence of such publication bias in any of the tests that we performed, but it remains one possible alternative explanation of our findings. Second, our result was based on unadjusted estimates, while a more precise analysis should be conducted adjusted by other factors like age, sex, and smoking and drinking status. Lack of information for data analysis may cause serious confounding bias. Third, not all studies including controls were in Hardy-Weinberg equilibrium. 20, 22, 24 Fourth, the association in this meta-analysis was investigated in all types of cases (hereditary, familial or sporadic PCa). There may be PCa-specific genetic effects among these cases but we could not obtain enough information to further estimate these effects. In addition, controls were not uniformly defined. Although most of the controls were mainly selected from healthy populations, some had BPH, and non-differential misclassification bias was possible because these studies may have included controls that had different risks for developing PCa. Despite these limitations, our meta-analysis also had some advantages. First, the studies retrieved were the latest, half of which were published in 2010 or 2009. Second, the quality of case-control studies included in current meta-analysis was satisfactory and met our inclusion criteria. Third, we did not detect any publication bias, indicating that all pooled results should be unbiased.
Conclusions
This meta-analysis did not show significant evidence that IL-10 À1082 A4G, À819 C4T and À592 C4A polymorphisms might be associated with PCa risk. However, IL-10 À819 C4T and À592 C4A polymorphisms might impact PCa progression. Patients carrying 819T, 592A were at higher risk for progression. Further prospective investigations with larger numbers of worldwide participants are needed to examine associations between IL-10 polymorphisms and PCa risk and aggressiveness to derive a comprehensive and true conclusion, and other possible confounding risk factors, such as age, sex, life style and race, should also be controlled.
